Girod A, Storrie B, Simpson J C, Johannes L, Goud B, Roberts L M, Lord J M, Nilsson T, Pepperkok R
Cell Biology and Biophysics Programme, EMBL Heidelberg, Meyerhofstrasse 1, 69117 Heidelberg, Germany.
Nat Cell Biol. 1999 Nov;1(7):423-30. doi: 10.1038/15658.
The cytosolic coat-protein complex COP-I interacts with cytoplasmic 'retrieval' signals present in membrane proteins that cycle between the endoplasmic reticulum (ER) and the Golgi complex, and is required for both anterograde and retrograde transport in the secretory pathway. Here we study the role of COP-I in Golgi-to-ER transport of several distinct marker molecules. Microinjection of anti-COP-I antibodies inhibits retrieval of the lectin-like molecule ERGIC-53 and of the KDEL receptor from the Golgi to the ER. Transport to the ER of protein toxins, which contain a sequence that is recognized by the KDEL receptor, is also inhibited. In contrast, microinjection of anti-COP-I antibodies or expression of a GTP-restricted Arf-1 mutant does not interfere with Golgi-to-ER transport of Shiga toxin/Shiga-like toxin-1 or with the apparent recycling to the ER of Golgi-resident glycosylation enzymes. Overexpression of a GDP-restricted mutant of Rab6 blocks transport to the ER of Shiga toxin/Shiga-like toxin-1 and glycosylation enzymes, but not of ERGIC-53, the KDEL receptor or KDEL-containing toxins. These data indicate the existence of at least two distinct pathways for Golgi-to-ER transport, one COP-I dependent and the other COP-I independent. The COP-I-independent pathway is specifically regulated by Rab6 and is used by Golgi glycosylation enzymes and Shiga toxin/Shiga-like toxin-1.
胞质衣被蛋白复合物COP-I与存在于在内质网(ER)和高尔基体复合物之间循环的膜蛋白中的细胞质“回收”信号相互作用,并且是分泌途径中顺行和逆行运输所必需的。在这里,我们研究了COP-I在几种不同标记分子从高尔基体到内质网运输中的作用。显微注射抗COP-I抗体可抑制凝集素样分子ERGIC-53和KDEL受体从高尔基体到内质网的回收。含有被KDEL受体识别序列的蛋白毒素向内质网的运输也受到抑制。相比之下,显微注射抗COP-I抗体或表达GTP受限的Arf-1突变体并不干扰志贺毒素/志贺样毒素-1从高尔基体到内质网的运输,也不干扰高尔基体驻留糖基化酶明显向内质网的循环。Rab6的GDP受限突变体的过表达会阻断志贺毒素/志贺样毒素-1和糖基化酶向内质网的运输,但不会阻断ERGIC-53、KDEL受体或含KDEL毒素的运输。这些数据表明存在至少两种不同的从高尔基体到内质网的运输途径,一种依赖COP-I,另一种不依赖COP-I。不依赖COP-I的途径由Rab6特异性调节,并且被高尔基体糖基化酶和志贺毒素/志贺样毒素-1所利用。